Breaks Categories: News

TuesdayJan 24, 2017 9:42 am

NetworkNewsBreaks – CAS Medical Systems, Inc. (NASDAQ: CASM) Demonstrates Impressive Sales Growth with FORE-SIGHT Cerebral Oximetry

CAS Medical Systems (NASDAQ: CASM) is a medical technology company that develops, manufactures and markets non-invasive patient monitoring products such as its FORE-SIGHT® Cerebral Oximeters. This innovative technology provides a highly accurate, non-invasive measurement of tissue oxygenation in the brain, enabling medical providers to improve patient care. The company recently reported preliminary unaudited top-line results for the three and 12 months ended December 31, 2016. Among other impressive figures, FORE-SIGHT Cerebral Oximetry sales increased 17% to approximately $18.0 million for 2016. The company estimated net sales for 2016 at approximately $22.2 million, up 14% from $19.5 million for 2015. For…

Continue Reading

FridayJan 20, 2017 1:26 pm

NetworkNewsBreaks – Concert Pharmaceuticals’ (NASDAQ: CNCE) CTP-656 Obtains Orphan Drug Designation from FDA

Concert Pharmaceuticals (NASDAQ: CNCE) this morning reported that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for CTP-656, a next generation CFTR potentiator for the treatment of cystic fibrosis. The designation provides incentives such as tax credits related to clinical trial expenses, an exemption from the FDA user fee, FDA assistance in clinical trial design, and potential market exclusivity for seven years following approval. In December 2016, Concert initiated a phase 2 trial in the U.S. evaluating CTP-656 in cystic fibrosis patients with gating mutations. Topline data from the ongoing phase 2 trial is expected by…

Continue Reading

ThursdayJan 19, 2017 11:53 am

NetworkNewsBreaks – PURE Bioscience, Inc. (PURE): 2017 Poised to be ‘Breakout Year’

Demonstrating the growing acceptance for its antimicrobial products, PURE Bioscience (OTCQB: PURE) recently posted first-quarter revenues of $531,000, up 186% year-over-year. Core food safety revenues increased 902% year-over-year, an achievement the company attributes to the accelerating momentum of its focused food safety strategy. PURE is pursuing regulatory approval for use of PURE Control in poultry online reprocessing, and said it expects FDA and USDA approvals in the second quarter of 2017. In its earnings release, company CEO Hank Lambert forecasts calendar 2017 as PURE’s “breakout year.” To learn more visit www.purebio.com About PURE Bioscience, Inc. PURE Bioscience, Inc. is focused…

Continue Reading

ThursdayJan 19, 2017 11:51 am

NetworkNewsBreaks – Sphere 3D (NASDAQ: ANY) Inks Deal to Acquire HVE and Unified ConneXions; Shares Higher

Shares of Sphere 3D (NASDAQ: ANY) are up 28% after the data management company said it will acquire HVE (Hybrid Virtualization Engine) ConneXions and its sister company, Unified ConneXions, Inc., which achieved combined virtualization revenue of more than $7 million for calendar year 2016. The acquired companies’ products, technologies and professional services will expand Sphere 3D’s virtualization practice and increase its ability to accelerate the delivery of hybrid cloud solutions. The acquisition is anticipated to close before January 31, 2017, and is expected to be accretive in the first quarter of 2017.  “UCX has exceptional leadership teams, innovative technology, industry…

Continue Reading

WednesdayJan 18, 2017 2:19 pm

NetworkNewsBreaks – BiondVax Pharmaceuticals’ (NASDAQ: BVXV) Flu Vaccine Candidate Shows Potential to Cover Mutating Strains

One of the primary concerns of conventional vaccination is historically low efficacy.  BiondVax (NASDAQ: BVXV), which earlier this month received an investment of $2.8 million to continue its development, is focused on creating a universal flu vaccine that would provide effective, multi-season protection. The company’s M-001 vaccine was recently featured in peer-reviewed scientific journal Vaccine, which reports that M-001 administered in the 2011 flu season significantly increased protective antibodies against the strain (A/Swiss) that caused the 2014/2015 influenza epidemic. Notably, the A/Swiss strain did not exist when M-001 was administered several years before. The results demonstrate M-001’s ability to provide…

Continue Reading

WednesdayJan 18, 2017 1:21 pm

NetworkNewsBreaks – Apricus Biosciences (NASDAQ: APRI) Shares Skyrocket on Approval of Vitaros® in Mexico

Shares of Apricus Biosciences (NASDAQ: APRI) soared more than 153% after the company announced that Mexico has granted Apricus’ commercialization partner, Ferring Pharmaceuticals, market approval for Vitaros®, an on-demand topical cream for erectile dysfunction. Per an agreement between the two companies, Apricus has received a total of $4.5 million in upfront payments from Ferring, in addition to a regulatory milestone payment of $1.6 million. Apricus is eligible to receive up to an additional $28 million in regulatory, launch and sales milestones, plus royalties on future net sales. Ferring is anticipated to launch in Mexico and Argentina during the second quarter…

Continue Reading

TuesdayJan 17, 2017 2:46 pm

NetworkNewsBreaks – Alcobra (NASDAQ: ADHD) Shares Plunge on Disappointing Results of MDX Clinical Trial

Shares of Alcobra (NASDAQ: ADHD) slumped 49% today after the company reported top-line results from MEASURE, its second phase 3 clinical trial for the investigational product Metadoxine Extended Release (MDX) for the treatment of ADHD in adult patients. MDX did not meet the primary endpoint of demonstrating a statistically significant difference from placebo in the change from baseline of the investigator rating of the Conners’ Adult ADHD Rating Scales (CAARS). "We are exceedingly disappointed with these top-line results. In the coming weeks, the Company intends to review the full data set from MEASURE. Consequently, we will evaluate our options and…

Continue Reading

TuesdayJan 17, 2017 12:17 pm

NetworkNewsBreaks – Gevo, Inc. (NASDAQ: GEVO) Receives EPA Pathway Approval for Isobutanol as Advanced Biofuel

Gevo (NASDAQ: GEVO) this morning said it has received EPA approval for the pathway for isobutanol to be an advanced biofuel under the Renewable Fuel Standard Program (RFS). This development presents an opportunity for Gevo to achieve the 50% or greater greenhouse gas emissions reduction needed to claim the advanced D5 Renewable Identification Number (RIN). Gevo’s isobutanol currently generates D6 RINs, and with this approval, it could generate D5 RINs as well, which have historically had greater value in the marketplace. “We are pleased that there is now a route for advanced fuels that provides protein that contributes to the…

Continue Reading

TuesdayJan 17, 2017 12:15 pm

NetworkNewsBreaks – Celsion (NASDAQ: CLSN) Shares Hike on Positive Data from the OVATION Study

Shares of Celsion (NASDAQ: CLSN) are up 37% after the company reported positive data from the fourth cohort of patients in its phase Ib dose escalating clinical trial (the OVATION Study). The study combines GEN-1, the company's IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of newly diagnosed patients with stage III and IV ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery. The study has produced significant results, with no dose limiting toxicities and promising efficacy signals in this difficult to treat cancer. Celsion said it expects to report final data in Q2…

Continue Reading

ThursdayJan 12, 2017 4:05 pm

NetworkNewsBreaks – Ur-Energy, Inc. (NYSE: URG) Posts Operation Rates above Initial Projections, Reliable Cash Flow

Ur-Energy (NYSE MKT: URG) recently posted its operational results for fourth quarter and year-end 2016, also reporting operational highlights and recent developments such as uranium sales for its Lost Creek in-situ recovery (ISR) uranium facility in south-central Wyoming. Contract sales for the fourth quarter from Lost Creek-produced U3O8 totaled 100,000 pounds at an average price of $32.70 per pound, for sales revenues of $3.3 million. For the year, the company had 662,000 pounds of U3O8 under contract at an average price of $47.61. “Our operations in 2016 continued at rates still well above initial projections for this period in Lost…

Continue Reading